

Eligible Population	Key Components	Recommendation	Frequency		
Adults 18 years or older	<b>Assessment and Diagnosis</b>	<p>The basic assessment has three purposes 1) to determine cause of the incontinence, 2) to detect related urinary tract and nervous system pathology and 3) to evaluate patient comprehensively.</p> <p>Assessment includes:</p> <ul style="list-style-type: none"> <li>• Physical exam (including genital system exam)</li> <li>• Mental status exam</li> <li>• Complete urinary history:               <ul style="list-style-type: none"> <li>➢ Duration and characteristics of UI (consider having patient do a voiding diary)</li> <li>➢ Frequency, timing and amount of continent and incontinent voids</li> <li>➢ Precipitants and associated symptoms of incontinence</li> <li>➢ Fluid intake pattern</li> <li>➢ Alterations in bowel habits and sexual function</li> <li>➢ Previous treatment and its effect on UI</li> <li>➢ Use of pads, briefs, or other devices</li> </ul> </li> <li>• Review of comorbidities</li> <li>• Review medications; common categories associated with UI:               <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <ul style="list-style-type: none"> <li>➢ Major tranquilizers</li> <li>➢ Antidepressants</li> <li>➢ Anticholinergics</li> <li>➢ Sedatives</li> <li>➢ Anti-Parkinson's-disease drugs</li> <li>➢ Antihistaminics</li> <li>➢ Antiarrhythmics</li> </ul> </td> <td style="width: 50%; vertical-align: top;"> <ul style="list-style-type: none"> <li>➢ Diuretics</li> <li>➢ Antihypertensives</li> <li>➢ Narcotics</li> <li>➢ H<sub>2</sub> antagonists</li> <li>➢ Anticonvulsants</li> <li>➢ α-Adrenergics</li> <li>➢ Others (alcohol, caffeine, or nicotine)</li> </ul> </td> </tr> </table> </li> <li>• Review of environment</li> <li>• Review of quality of life issues</li> <li>• Review of availability of resources</li> </ul> <p>Tests for assessment of UI:</p> <ul style="list-style-type: none"> <li>• Cough-test for suspected UI</li> <li>• Urinalysis with culture</li> <li>• Postvoid residual (PVR) urine measurement</li> </ul>	<ul style="list-style-type: none"> <li>➢ Major tranquilizers</li> <li>➢ Antidepressants</li> <li>➢ Anticholinergics</li> <li>➢ Sedatives</li> <li>➢ Anti-Parkinson's-disease drugs</li> <li>➢ Antihistaminics</li> <li>➢ Antiarrhythmics</li> </ul>	<ul style="list-style-type: none"> <li>➢ Diuretics</li> <li>➢ Antihypertensives</li> <li>➢ Narcotics</li> <li>➢ H<sub>2</sub> antagonists</li> <li>➢ Anticonvulsants</li> <li>➢ α-Adrenergics</li> <li>➢ Others (alcohol, caffeine, or nicotine)</li> </ul>	<p>Comprehensive exam at initial visit, and as needed for new UI symptoms or changes in UI symptoms.</p> <p>Urinary symptom history at least annually or more frequently as needed for patients at risk for UI or with history of UI; every two years for all others.</p>
<ul style="list-style-type: none"> <li>➢ Major tranquilizers</li> <li>➢ Antidepressants</li> <li>➢ Anticholinergics</li> <li>➢ Sedatives</li> <li>➢ Anti-Parkinson's-disease drugs</li> <li>➢ Antihistaminics</li> <li>➢ Antiarrhythmics</li> </ul>	<ul style="list-style-type: none"> <li>➢ Diuretics</li> <li>➢ Antihypertensives</li> <li>➢ Narcotics</li> <li>➢ H<sub>2</sub> antagonists</li> <li>➢ Anticonvulsants</li> <li>➢ α-Adrenergics</li> <li>➢ Others (alcohol, caffeine, or nicotine)</li> </ul>				

Eligible Population	Key Components	Recommendation	Frequency
<p>Individuals with a potentially reversible cause for UI</p>	<p><b>Management:</b> <b>Discuss treatment options with patient, family, or caregiver</b></p>	<p>Individuals identified as having a potentially reversible (<b>DIAPPERS</b>) cause for UI:</p> <ul style="list-style-type: none"> <li><b>D</b> Delirium (commonly related to medication or acute illness)</li> <li><b>I</b> Infection (especially from urinary tract)</li> <li><b>A</b> Atrophic urethritis/vaginitis (frequent source of UTI, including incontinence)</li> <li><b>P</b> Psychiatric disorders (primarily depression)</li> <li><b>P</b> Pharmaceuticals</li> <li><b>E</b> Excess Urine Output (excess fluid intake, metabolic disorders, medications or medical conditions)</li> <li><b>R</b> Restricted mobility</li> <li><b>S</b> Stool impaction</li> </ul> <p>Conservative treatments for suspected or identified UI with a reversible cause, use one or a combination of the following:</p> <ul style="list-style-type: none"> <li>• <b>Bladder Retraining:</b> Scheduled voiding urgency-control strategies, self-monitoring of voiding behavior, a trial period of no less than 6 weeks</li> <li>• <b>Pelvic Floor Muscle training (PFMT):</b> Also known as Kegel exercise; consider Physical Therapy referral for individuals who have trouble doing Kegel exercises; should be continued for at least 12 weeks</li> <li>• <b>Lifestyle modifications:</b> Weight loss, limit fluid and urinary irritants (caffeine, alcohol, or nicotine), eliminate environment factors that interfere with toileting</li> <li>• <b>Pharmacologic intervention:</b> Optimal treatment should be individualized, considering the patient’s co-morbidities, concomitant medications and the pharmacological profiles of the different drugs. Pharmacotherapy for UI is best used as an adjuvant to conservative and/or surgical therapy.               <ul style="list-style-type: none"> <li>➤ <b>Hormones:</b> Topical estrogen - for atropic urethritis and/or vaginitis in women; Desmopressin - for nocturia (care should be taken because of the risk of hyponatremia, especially in the elderly)</li> <li>➤ <b>Antimuscarinic drugs</b></li> <li>➤ <b>Antidepressants</b></li> <li>➤ <b>Alpha-adrenoreceptor antagonists:</b> For men with BPH (Benign Prostatic Hypertrophy)</li> <li>➤ <b>Phosphodiesterase 5 inhibitors:</b> For male LUTS (Lower Urinary Tract Symptoms) / OAB (Overactive Bladder)</li> </ul> </li> </ul>	<p>Assess response to treatment within 12 weeks</p>

Eligible Population	Key Components	Recommendation	Frequency
Failure of conservative treatment or for those with complex urinary incontinence	<b>Specialist referral</b>	<p>Those who have failed conservative treatment or have complex urinary incontinence should be referred to a specialist for management. The complex UI group comprises patients with incontinence associated with:</p> <ul style="list-style-type: none"> <li>• Pain</li> <li>• Hematuria</li> <li>• Recurrent infection</li> <li>• Previous failed incontinence surgery</li> <li>• Total incontinence</li> <li>• Voiding dysfunction PVR &gt; 200 (e.g. due to bladder obstruction), poor bladder emptying may be suspected from symptoms, physical exam, or if imaging has been performed by ultrasound or X-ray after voiding</li> <li>• Previous pelvic radiotherapy and/or radical pelvic surgery</li> <li>• Suspected pelvic organ abnormality (e.g. fistula, prolapsed organ, or mass)</li> </ul>	Referral should be considered if initial treatment is unsuccessful after a reasonable period of time (e.g. 8- 12 weeks)
	<b>Education and risk factor modification</b>	<p><b>Educate patient/family /caregiver regarding:</b></p> <ul style="list-style-type: none"> <li>• <b>Lifestyle changes:</b> Lose weight if overweight; avoid constipation as repeated straining can damage the pelvic floor; drink less fluids or stop fluid intake prior to bedtime if nocturia or enuresis is a problem; limit intake of caffeine; stop smoking; seek treatment for frequent coughing; eliminate physical barriers that interfere with toileting</li> <li>• <b>Bladder Training:</b> Gradually increase time intervals between urinating by controlling the urge to empty (every 3-4 hrs during the day, and every 4-8 hrs at night); should be tried for minimum of 6 weeks</li> <li>• <b>Pelvic Floor Muscle Training (PFMT)/Kegel Exercises:</b> Squeeze the muscles that you use to stop the flow of urine, hold up to 10 seconds, then release. Repeat 10-20 times at least 3 times a day. It may take up to 4-6 weeks to notice an improvement in symptoms, and should be continued for at least 12 weeks.</li> <li>• <b>Medications:</b> Medication schedule, actions, potential side effects, and any potential interactions with other medications</li> </ul>	

This guideline is based on several sources, including: Guidelines on Urinary Incontinence, European Association of Urology, 2010; Quality Indicators for the Screening and Care of Urinary Incontinence in Vulnerable Elders, Journal American Geriatric Society, October 2007-Vol. 55, No. S2 S443-449; Basic Assessment of Urinary Incontinence, Southern Medical Journal, Vol. 95, No. 2, pp 178-182, February 2002

UPHP CAC Approved 12-8-2010